Sequential multiple assignment randomized trials (SMARTs) are the gold standard trial design to generate data for the evaluation of multi-stage treatment regimes. As with conventional (single-stage) randomized clinical trials, interim monitoring allows early stopping; however, there are few methods for principled interim analysis in SMARTs. Because SMARTs involve multiple stages of treatment, a key challenge is that not all enrolled participants will have progressed through all treatment stages at the time of an interim analysis. Wu et al. (2021) propose an estimator for the mean outcome under a given regime that uses data only from participants who have completed all treatment stages. We propose a doubly-robust estimator for the mean outcome under a given regime that gains efficiency by using partial information from enrolled participants regardless of their progression through treatment stages. Using the asymptotic distribution of this estimator, we derive associated Pocock and O'Brien-Fleming testing procedures for early stopping. In simulation experiments, the estimator controls type I error and achieves nominal power while reducing expected sample size relative to the method of Wu et al. (2021). We provide an illustrative application of the proposed estimator using a case study based on a recent SMART evaluating behavioral pain interventions for breast cancer patients.
翻译:由于SMART系统涉及多个治疗阶段,一个关键挑战是,并非所有注册的参与者在临时分析时都会在所有治疗阶段都取得进展。Wu等人(2021年)提议对某一制度下的平均结果进行估算,该制度只使用已完成所有治疗阶段的参与者提供的数据。我们提议对某一制度下的平均结果进行双重紫外线估测,同时在某一制度下,通过使用注册参与者提供的部分信息提高效率,而不论其在治疗阶段的演进如何,通过使用部分信息提高效率。我们利用这一估算器的无序分布,得出了相关的Pocock和O'Brien-Fleming测试程序,以便及早停止。在模拟实验中,估计器控制了I类错误,并实现了名义能力,同时减少了与最近以WOASMA系统为例的癌症治疗方法相比的预期样本规模(2021年)。